Fred Hutchinson Cancer Research Center
Clinical Research Division
Member, Appointed: 1996
Fred Hutchinson Cancer Research Center
Penny L. Peterson Endowed Chair, Appointed: 2001
University of Washington Medical Center
Professor, Appointed: 1996
M.D., University of Washington, Medical Scientist Training Program, 1979.
Ph.D., University of Washington, Biological Structure, 1977.
B.S., Stanford University, Biology, 1973.
My program is devoted to the investigation of novel treatments for hematologic malignancies including non-Hodgkin's lymphoma and acute and chronic leukemias. We conduct basic laboratory investigations using leukemia and lymphoma cell lines and mouse xenograft models as well as human clinical trials. Agents currently under investigation include monoclonal antibodies, radioimmunoconjugates, immunotoxins, chemotherapeutic agents, and genetically modified cytotoxic T lymphocytes. In the clinical arena, we are continuing our successful program of high dose radioimmunotherapy with stem cell transplantation for B cell lymphomas and have trials planned investigating pretargeted radioimmunotherapy and gene therapy using adoptively transferred cytotoxic T lymphocytes bearing chimeric anti-CD20 receptors.
Postgraduate Training in Internal Medicine:
Fellow in Oncology, University of Washington/Fred Hutchinson Cancer Research Center, 1983-1986
Chief Residency, University of Washington Medical Center, Seattle, 1982-1983
Residency, Massachusetts General Hospital, Boston, 1980-1982
Internship, Massachusetts General Hospital, Boston, 1979-1980
Medical Oncology Certification (A.B.I.M.), November, 1985
American Board of Internal Medicine, Sept. 15, 1982
National Board of Medical Examiners, July 1, 1980
State of Washington, #20170 (8/6/82).
Associate Editor, Journal of the National Cancer Institute, 1991-1995
Managing Editor, annals of Hematology, 1998-2001
Editor, Blood, 2001-present
Editor, Journal of Therapeutic Immunology, 1995-1999
Editor, Advances in Leukemia/Lymphoma
Editor, Tumor Targeting
Editor, Cancer Biotherapy and Radiopharmaceuticals
Editor, Cytokines, Cellular & Molecular Therapy
Reviewer, Cancer Research/Clinical Cancer Research/Journal of Immunology/Journal of Clinical Oncology/Blood/Chest.
American Association for Cancer Research
American Association of Physicians
American Federation for Clinical Research, Councilor for Washington
American Medical Association
American Society for Clinical Investigation
American Society for Clinical Oncology
American Society for Gene Therapy
American Society of Hematology
Southwest Oncology Group
Honors and Awards
2009, Co-Chair, Lymphoma Steering Committee, National Cancer Institute
2007, Ellen Glesby Cohen Leadership Award, Lymphoma Research Foundation
2005, Chairman, Scientific Advisory Board, Lymphoma Research Foundation
2002, Selected as one of Seattle's 'Best Doctors', Seattle Magazine
2001-2003, Selected as one of 'America's Top Doctors',
2000, Election to the American Association of Physicians ('Old Turks'),
1998, CRS-Cygnus Award for Outstanding Work in Drug Delivery,
1996, Election to the American Society for Clinical Investigation ('Young Turks'),
1993-1995, Recipient of the first Boeing Corporate Medical Research Award,
1988-1989, Elsa Pardee Award for Cancer Research,
1987-1992, First Independent Research and Training Award from the National Institutes of Health,
1985-1986, Young Investigator Award from the American Society for Clinical Oncology,
1985-1988, Clinical Oncology Career Development Award from the American Cancer Society,
1979, PhD Thesis Honors, University of Washington
1979, Medical Auxiliary MD, PhD Award,
1979, Graduation with 'Highest Honors' from University of Washington School of Medicine,
1979, Robert S. Evans Award,
1979, John J. Bonica Prize in Anesthesiology,
1979, Lamport Biomedical Research Prize,
1979, Seattle Academy of Internal Medicine Prize,
1978, Scholarship from International College of Surgeons,
1976, Alpha Omega Alpha, Honorary Medical Fraternity (elected as 3rd year student in Spring, 1976),
1973, Phi Beta Kappa, Stanford University
1973, Departmental Honors and Departmental Distinction in Biology, Stanford University
1970-1973, George E. Gamble Honors Scholarship, Stanford University
2005-2009, Clinical Research in Hematology and Hematologic Malignancies, Seattle Cancer Care Alliance
1996-2007, Biological Structure, University of Washington, Biological Structure
1993-2000, Acting Program Director, University of Washington Medical Center, High-Dose Chemotherapy Unit
1991-1996, Associate Member, Fred Hutchinson Cancer Research Center
1991-2006, Associate Director, University of Washington, Medical Scientist Training Program
1991-1996, Associate Professor in Medicine, University of Washington
1991-2006, Associate Director, Medical Scientist Training Program, University of Washington, School of Medicine
1988-1991, Adjunct Assistant Professor of Biological Structure, University of Washington
1987-1991, Assistant Professor in Medicine, University of Washington
1986-1991, Assistant Member, Fred Hutchinson Cancer Research Center
1983-1986, Senior Fellow, Fred Hutchinson Cancer Research Center
1982-1986, Acting Instructor in Medicine, University of Washington
1979-1982, Clinical Fellow in Medicine, Harvard University, Medical School
Active (active period marked with *)
|NCI Program Project Grant, PO1 CA044991, Overall P.I.: O.W. Press, “Therapy of Lymphoma/Leukemia with Monoclonal Antibodies.” This program project grant is developing improved strategies for treating patients with hematologic malignancies using radiolabeled monoclonal antibodies. It contains human clinical trials of high dose radioimmunotherapy with stem cell transplantation for leukemia (Project 1), lymphoma (Project 2) and for pretargeted radioimmunotherapy of hematologic malignancies (Project 3).This grant has been competitively renewed five times. $1,503,362/current year, $6,811,145/entire project [direct costs].
|NCI R01 CA076287, P.I.: O.W. Press, “Pretargeted Radioimmunotherapy of CD20+ NHL.” This grant investigates the potential of streptavidin-biotin pretargeting for amplifying the effects of radioimmunotherapy of lymphomas in mouse models. It has been competitively renewed twice. $246,389/current year, $1,270,045/entire project [direct costs].
|NIH R01 CA109663, P.I.: O.W. Press, “CD45 Pretargeted Radioimmunotherapy for AML.” This grant investigates the potential of streptavidin-biotin pretargeting of CD45 for amplifying the effects of radioimmunotherapy of acute leukemia in mouse models. $193,084/current year, $1,069,375/entire project [direct
||NCI R01 CA136639, P.I.: O.W. Press, “Bispecific Antibody Engineering for AML Radioimmunotherapy.” This grant studies molecularly engineered bispecific antibodies and radiolabeled ligands as an alternative to streptavidin-biotin pretargeting for amplifying the effects of radioimmunotherapy of AML in mouse models. $257,824/current year, $1,288,545/ entire project [direct costs].
||NCI R01 CA154897, P.I.: O.W. Press, “CD38 Pretargeted Radioimmunotherapy for Myeloma” Aim 1. To characterize the pharmacokinetics, biodistribution and dosimetry of radio-biotin pretargeted with an anti-CD38 OKT10 (scFv)4-streptavidin fusion protein (OKT10-FP) to human myeloma cells in a mouse subcutaneous xenograft model and a SCID-hu mouse model bearing human multiple myeloma cells with human stromal microenvironment. Aim 2: To evaluate the therapeutic efficacy of 90Y radiolabeled DOTA-biotin targeted to myeloma xenografts in athymic mice and malignant plasma cells in SCID-hu mouse myeloma models. Aim 3: To assess the impact of CD38 antigen upregulation induced by all-trans-retinoic acid (ATRA) on the biodistribution and therapeutic efficacy of radiolabeled DOTA-biotin targeted to mouse myeloma xenografts; and malignant plasma cells in SCID-hu mouse myeloma models. Aim 4: To investigate the toxicity and efficacy of combination therapy using anti-CD38 PRIT, with and without lenalidomide and/or bortezomib, in a mouse subcutaneous myeloma xenograft model and a SCID-hu mouse model.$231,352/current year, $1,079,845/entire project [direct costs].
||R21EB014572, PI: Stayton, P., Subaward from the University of Washington. Subaward P.I.: Press, O.W., “Intracellular delivery of Proapoptotic peptide drugs for the treatment of cancer.” The overall goal of this research is to design and synthesize a targeted, polymeric carrier that can be utilized to delivery pro-apoptotic peptides to enhance tumor cell death in vivo. $51,045 direct costs.
Completed Major Competitive Grant Research Support
||Life Sciences Discovery Fund – Washington State 08-02, P.I. & Director: P. Stayton, P; Co-Director: O.W. Press, “Center for Intracellular Delivery of Biologics.” This proposal aims to create a new Center for Intracellular Delivery of Biologics (CIDB) that would bring together an interdisciplinary team to address this Grand Challenge. The drug delivery systems would navigate both systemic circulation barriers and the special barrier of intracellular trafficking. Overall grant: $1,432,758, direct costs current year. Subaward from University of Washington, P.I.: O.W. Press. $133,296 direct costs current year.
|Leukemia & Lymphoma Society 7008, Overall PI: I. Bernstein, P.I. Project I: O.W. Press, “Immunotherapy of Hematological Malignancies.” This program is evaluating clinical trials of non-myeloablative allogeneic transplantation for patients with lymphomas and leukemias using reduced intensity conditioning regimens containing radiolabeled anti-CD20 and anti-CD45 monoclonal antibodies. This grant has been competitively renewed. Project I: $250,000/current year; $1,000,000/entire project [direct costs].
||NIDDK 5 P30 DK056465, CCEH Pilot Grant, P.I.: O.W. Press, “Genetic Modification of Human Hematopoietic Stem Cells to Confer Chemotherapy Drug Resistance.” $20,000 [direct costs].
||NIH R21 CA 117131, PI: O.W. Press, “CTL Therapy of Mantle Cell Lymphoma.” This grant supported a clinical trial of adoptive T cell immunotherapy of relapsed B cell lymphomas using polyclonal populations of T lymphocytes genetically modified to express a “2nd generation” chimeric T cell receptor. $289,852 entire project, direct costs.
||Edson Foundation P.I.: O.W. Press. This grant supported immunotherapy studies for leukemia, lymphoma, and myeloma. $50,000 per year for three years.
||Charlotte Geyer Foundation, P.I.: O.W. Press. This award supported preliminary work on “Bispecific Antibody Pretargeted Radioimmunotherapy of AML.” $169,000, direct costs.
||Britton-Simmons Foundation, P.I.: O.W. Press, $100,000 to support research studies.
||NIH R01 CA92302, “Chimeric Anti CD20 T Cell Receptors for Lymphoma Therapy” PI O. Press, $862,009/entire project [direct costs]. These studies will assess the feasibility and safety of transfecting CD8+ cytotoxic lymphocytes with chimeric anti-CD20 T cell receptors and administering them to patients with relapsed B cell lymphomas.
|NIH R01 CA55596, P.I.: O.W. Press, “Intracellular Trafficking of Immunotoxins.” The aims of this project were to study the intracellular routing and translocation of ricin A chain immunotoxins in malignant leukemic and lymphoid cells. This grant was competitively renewed twice. $823,187, direct costs.
|Department of Energy Grant #DE-FG-06-92ER61459, P.I.: O.W. Press, “Improved Radioimmunotherapy of Hematologic Malignancies.” The aims were to study the rates of endocytosis, intracellular routing, and metabolic degradation of radiolabeled monoclonal antibodies targeting tumor associated antigens on human leukemia and lymphoma cells; to examine the effects of maximally tolerated doses of lysosomotropic amines, carboxylic ionophores, and thioamides on radio-immunoscintigraphy and radioimmunotherapy in an in vivo tumor xenograft system; to examine the impact of newer radioiodination techniques on the metabolic degradation of radioiodinated antibodies, and the radioimmuno-scintigraphy and radioimmunotherapy of neoplasms; and to compare the endocytosis, intracellular routing, and degradation of radioimmunoconjugates prepared with different radionuclides. This grant was competitively renewed twice (including a supplement in 1991-92). $556,410, direct costs.
||Seattle Foundation Equipment Grant, P.I.: O.W. Press, "Improved Immunotoxin Therapy of Human Leukemia and Lymphoma." This was a supplemental award permitting purchase of laboratory equipment for immunotoxin synthesis and purification. $15,000, direct costs.
||RGK Foundation Grant, P.I.: O.W. Press, “Antibody Therapy,” This grant supported a fellow’s stipend to work in the laboratory on radioimmunotherapy of breast cancer tumor xenografts. $25,000, direct costs.
||NIH First Independent Research and Training Award, R29 CA 46134, P.I.: O.W. Press, “Receptor Mediated Endocytosis of Lymphocyte Antigens.” This study evaluated the internalization and intracellular targeting of monoclonal antibody immunoconjugates by malignant hematopoietic cell lines. $325,000, direct costs.
||American Cancer Society Institutional Cancer Grant, P.I.: O.W. Press, "Her-2neu Oncogene Antibody." This pilot study investigated treatment of breast cancer with radiolabeled antibodies targeting the Her-2/neu oncoprotein. $5,832, direct costs.
||Elsa Pardee Award for Cancer Research, P.I.: O.W. Press, “Radioimmunotherapy of Hematologic Malignancies.” This pilot study investigated intracellular degradation of radioimmunoconjugates by malignant cells. $25,370, direct costs.
||American Cancer Society Special Research Grant, P.I.: O.W. Press, “Receptor Mediated Endocytosis of Lymphocyte Antigens.” $289,000, direct costs. This grant was declined because it overlapped with the NIH FIRST Award.
||American Cancer Society Career Development Award, #85-35, P.I.: O.W. Press, $35,000/year stipend for three years.
||American Society of Clinical Oncology Young Investigator Award - P.I.: O.W. Press, $25,000 stipend.
||American Cancer Society Institutional Cancer Grant 65-2633, P.I.: O.W. Press, "Evaluation of Immunotoxin Efficacy." This pilot study investigated the use of ricin A chain immunotoxins for prevention of graft versus host disease. $6,650, direct costs.